Enclomiphene vs TRT: Which Fits Low Testosterone?

How each one works

Testosterone therapy supplies testosterone from outside the body, by injection, gel, pellet, or capsule. Your brain senses the supply and turns down its own signal to the testes (LH and FSH), so natural production falls. See the delivery methods.

Enclomiphene works the other way. It is a selective estrogen receptor modulator (SERM). It blocks estrogen's braking signal in the brain, so the brain raises LH and FSH, and the testes make more testosterone themselves. Doctors describe this as restoration rather than replacement. Clomiphene, an older drug with the same mechanism, is a mix of two forms, and enclomiphene is the one thought to do the useful work.

Who can use which

This is the most important filter, and it comes from your labs, not your preference.

• TTRT works for either cause of low T, primary (testes not responding) or secondary (weak signal from the brain), because it supplies testosterone directly.
• EEnclomiphene needs a working response. It makes sense when testosterone is low but LH is low or normal, meaning the testes can still make it if told to. In the large trials, men were required to have a morning testosterone at or below 300 ng/dL and LH below 9.4 IU/L. If LH is already high, the brain is already shouting and the testes aren't listening; more signal won't help. See primary vs. secondary low T.

The enclomiphene trials also enrolled overweight men aged 18 to 60. They don't tell us how it performs in older men or men with other conditions. A provider who offers enclomiphene without checking LH first is skipping the step that decides whether it can work.

What they do to testosterone levels

Both raise testosterone, but not to the same degree, and the comparisons are mostly with clomiphene, enclomiphene's older relative.

• Enclomiphene vs. testosterone gel: in a phase II trial, enclomiphene raised morning testosterone to levels similar to 1% testosterone gel. In two phase III trials of 16 weeks, it raised total testosterone in overweight men with secondary low T, and LH and FSH rose, while with 1.62% gel they fell.
• Clomiphene vs. TRT formats: in a single-center retrospective comparison of 93 treated men, median total testosterone ended at about 504 ng/dL on clomiphene, 1,014 on injections, and 412 on gels. Injections were higher than clomiphene, while clomiphene and gels were similar. A 2026 meta-analysis of 11 studies (1,512 men) found no significant overall difference between clomiphene and TRT, with a lot of variation between studies, and found injections reached higher levels than clomiphene in the one study that compared them.

The takeaway: for many men, enclomiphene or clomiphene can bring testosterone into the normal range, roughly where a gel would. Whether it gets your level where you need it depends on how well your testes respond, which is why follow-up labs matter.

What they do to how you feel

Here the evidence gets thin, and it is worth being plain about it.

• ?For enclomiphene itself, we found no head-to-head trial against TRT on symptoms. The pivotal trials measured testosterone, LH, FSH, and sperm. The abstracts we reviewed report no libido, energy, or mood outcomes. A 2016 expert review described the evidence as "initial."
• ≈For clomiphene, results are mixed. In the single-center comparison, overall symptoms and satisfaction scores were similar across clomiphene, injections, and gels, though libido scores were higher with injections. In the 2026 meta-analysis, libido scores were lower with clomiphene than with TRT (about half a point on a 5-point scale in three studies of 199 men), and the authors called their findings preliminary and called for larger randomized trials.

So the honest summary is: enclomiphene can raise your testosterone, and clomiphene data suggest symptom relief is often comparable but may be less on libido, but nobody has shown that enclomiphene relieves symptoms as well as TRT. Anyone telling you it is "just as effective" is going beyond the evidence. Our low T symptoms guide explains which symptoms are most likely to respond to any treatment.

Safety and unknowns

TRT's risks are well mapped, thanks to large trials like TRAVERSE: raised hematocrit, blood pressure effects, sleep apnea, fertility suppression, and the rest. See TRT side effects and monitoring.

For enclomiphene, the safety picture is much less complete:

• The trials were short (16 weeks for the phase III studies). Long-term safety hasn't been established in the evidence we reviewed.
• The abstracts we reviewed did not report hematocrit, headache, or other adverse-event rates. Ask any provider what monitoring they use.
• Estradiol rises when testosterone does, whichever route you take. See managing estrogen.
• The best long-term data are for clomiphene: a retrospective review of 400 men treated for a mean of about two years. Among men treated more than three years, 88% reached normal testosterone, estradiol rose significantly, and 8% reported side effects, most often mood changes, blurred vision, and breast tenderness. It is a retrospective chart review, not a randomized trial, and it is not enclomiphene.

Regulatory status and access

Enclomiphene is not FDA-approved for any use. It reaches patients through compounding pharmacies. In June 2022, an FDA advisory committee voted 8 to 4 against adding enclomiphene to the list of bulk substances eligible for compounding, partly over limited evidence of clinical benefit; that vote is advisory, and we found no later FDA action, but the status is unsettled. Compounded products are not FDA-approved products, and the quality and consistency can differ by pharmacy.

TRT, by contrast, comes as FDA-approved products with published label data. That doesn't make TRT better for every man, but it means the safety information is on the label and in large trials.

Testosterone is a Schedule III controlled substance, and prescribing rules for it are stricter than for most drugs. That is a legal difference, not a medical reason to choose one treatment over the other. In our reviews, Hims, for example, sells an enclomiphene-based daily pill (Rx+, with tadalafil and supplements) from $49/mo in medication, plus a required $49 membership; see the full list in providers offering oral options and enclomiphene.

Where fertility fits

Fertility is the clearest reason to consider enclomiphene. In the phase III trials, sperm concentration stayed in the normal range on enclomiphene and fell markedly on testosterone gel. If you want children now or soon, the AUA says testosterone should not be prescribed, and enclomiphene or clomiphene are among the options. We cover the evidence in detail in TRT and fertility, so it isn't repeated here.

Side by side, and questions to ask

Questions to ask a provider

• Did you check my LH and FSH before recommending enclomiphene?
• Is my low testosterone primary or secondary, and what is the evidence for that?
• Which compounding pharmacy supplies it, and is it licensed?
• What will you monitor (testosterone, LH, estradiol, blood count) and how often?
• What is the plan if my level doesn't come up, or my symptoms don't improve?
• How does the cost over a year compare with TRT? See our comparisons.

Sources

1. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. PubMed
2. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone. BJU Int. 2016;117(4):677-685. PubMed
3. Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016;17(11):1561-1567. PubMed
4. Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. 2014;192(3):875-879. PubMed
5. Constantinou BT, Benedicto BC, Galligani L, et al. Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2026;82(8):204. PubMed
6. Krzastek SC, Sharma D, Abdullah N, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. J Urol. 2019;202(5):1029-1035. PubMed
7. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. American Urological Association
8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, June 8, 2022 (enclomiphene citrate).